Developing a Bioluminescent Mouse Model for CAR T Cell Therapy in AML
Author Information
Author(s): Mireia Mayoral Safont, Calum Leitch, Mihaela Popa, May Eriksen Gjerstad, Benjamin Caulier, Else Marit Inderberg, Sébastien Wälchli, Pascal Gelebart, Emmet Mc Cormack
Primary Institution: University of Bergen
Hypothesis
Can a bioluminescent AML-PDX mouse model be developed to evaluate CAR T cell therapy?
Conclusion
The protocol successfully outlines the development of a bioluminescent AML-PDX model for evaluating CAR T cell therapy.
Supporting Evidence
- Patient-derived xenograft models capture the complexity of patient samples.
- The protocol details procedures for validating the AML-PDX model.
- Bioluminescence imaging allows for non-invasive monitoring of leukemia progression.
- The model can be used to evaluate other immunotherapeutic drugs.
- Transduction efficiency is crucial for establishing the bioluminescent model.
Takeaway
This study shows how to create a special mouse model that glows to help scientists test new cancer treatments using CAR T cells.
Methodology
The protocol includes steps for transducing, engrafting, expanding, and enriching AML-PDX cells, followed by in vitro and in vivo validation.
Limitations
The model requires immunodeficient mice, which may not fully replicate the human immune system, potentially affecting findings.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website